|
Amgen Posts Positive Phase I Results For Asthma Drug
BioResearch Online (press release) Amgen reported positive results from the Phase I study showing that inhibiting thymic stromal lymphopoietin (TSLP) could be useful in the treatment of asthma. TSLP is a cytokine considered to be a key driver of the allergic inflammation that … Anti-thymic stromal lymphopoietin therapy reduced allergy-induced … |
View full post on asthma – Google News